The four end-of-life drugs are a standardized set of injectable medications prescribed to manage the most common symptoms that arise in someone’s final days: an opioid such as morphine for pain and breathlessness, a sedative such as midazolam for agitation and anxiety, an anticholinergic such as hyoscine or glycopyrrolate for noisy respiratory secretions, and an antiemetic such as haloperidol for nausea and vomiting. This combination, widely used in the UK and increasingly adopted elsewhere, is often prescribed in advance and kept in the home so that nurses or caregivers can respond quickly when symptoms develop.1PubMed Central. Anticipatory prescribing in community end-of-life care: systematic review and narrative synthesis of the evidence since 2017 Each drug targets a distinct symptom, and understanding what they do can help families feel less alarmed when they appear at the bedside.
Morphine and Other Opioids for Pain and Breathlessness
Morphine is the most recognizable of the four. Its job in the final days extends beyond pain relief: opioids are also the first-choice treatment for the distressing sensation of breathlessness that often accompanies dying, particularly when the underlying cause can no longer be reversed.2PubMed. Dyspnea at End-of-Life For someone who has not been taking opioids previously, the doses used are low. Oral morphine at around 5 mg or a parenteral (injected) dose of 2 mg or less is often enough to bring noticeable relief.
In a study of patients with advanced heart failure, morphine reduced breathlessness scores substantially within 24 hours while leaving oxygen levels, blood pressure, and heart rate essentially unchanged.3PubMed. Experience of morphine therapy for refractory dyspnea as palliative care in advanced heart failure patients That finding is reassuring for families who worry that morphine will cause a sudden decline. The goal is comfort, and the doses used in end-of-life care are carefully titrated to match the symptom, not to sedate someone into unconsciousness.
There is no strong evidence pointing to one opioid being universally superior to another in this setting. A systematic review of pharmacological treatment in the last days of life found that the literature remains mostly descriptive, with no clear winner among the available opioids or a single ideal dose.4PubMed. Pharmacological treatment of pain, dyspnea, death rattle, fever, nausea, and vomiting in the last days of life in older people: A systematic review In practice, morphine is the default because clinicians know it well, it is inexpensive, and it has decades of use behind it. Alternatives like oxycodone, hydromorphone, or fentanyl may be chosen when morphine is not well tolerated or when kidney function is a concern.
Midazolam for Anxiety, Agitation, and Restlessness
Midazolam is a fast-acting benzodiazepine and is widely considered one of the four essential drugs for quality care in dying patients.5PubMed Central. Midazolam: an essential palliative care drug It works by enhancing the activity of a calming brain chemical (GABA), which gives it sedative, anti-anxiety, and anticonvulsant properties. For the dying person, this translates to relief from the agitation, restlessness, and fear that can surface in the final hours or days, a distressing state sometimes called terminal restlessness.
A clinical trial comparing intranasal and subcutaneous midazolam for agitation in terminal illness found that both routes reduced agitation scores significantly within five minutes, with further improvement at 20 minutes.6PubMed Central. A randomized controlled clinical trial of intranasal versus subcutaneous midazolam for agitation in terminal illness (MinTU study) That speed matters when someone is visibly distressed: families and patients benefit from knowing that relief does not take long to arrive.
Midazolam is by far the most commonly used medication for terminal agitation. In one analysis of prescribing patterns, midazolam was used in over 90% of cases compared with far lower rates for haloperidol and levomepromazine.7PubMed Central. Pharmacological Treatment for Terminal Agitation, Delirium and Anxiety in Frail Older Patients The typical dose in the last 24 hours ranged from about 2.5 mg when given on an as-needed basis to 10 mg or more when delivered as a continuous infusion. Doses can climb higher when both methods are combined, reflecting the reality that some patients need more than others.
An Anticholinergic for Respiratory Secretions
The rattling sound that can develop in someone’s breathing during the last hours of life, often called a death rattle, comes from saliva and mucus pooling in the throat and airways when the person is too weak to swallow or cough. It is usually more distressing for family members at the bedside than for the dying person themselves, who is typically unconscious or semi-conscious by this point.
The medications used to manage this are anticholinergics, which reduce mucus production. Common choices include glycopyrrolate, hyoscine (scopolamine), hyoscyamine, and atropine. Their effectiveness over placebo has not been firmly established, and patients whose noisy breathing stems from lung disease or infection rather than pooled secretions are less likely to respond.1PubMed Central. Anticipatory prescribing in community end-of-life care: systematic review and narrative synthesis of the evidence since 2017 This is one of the weaker links in the four-drug combination from a pure evidence standpoint. Still, because the sound of the rattle can be deeply upsetting to loved ones, clinicians often prescribe these agents as a measure of comfort for the family as well as the patient.
Whether to give anticholinergics preventively, before the rattle begins, or only once it develops remains an open question. There is ongoing debate about the balance between medicating a symptom that may not bother the dying person and providing reassurance to those watching.8Elsevier / Journal of Pain and Symptom Management. Should (Prophylactic) Medications Be Used for the Management of Death Rattle? In practice, many palliative care teams start with repositioning the person and gentle suctioning, turning to medication if the secretions persist.
Haloperidol for Nausea and Delirium
Haloperidol rounds out the standard four. It is an antipsychotic that blocks dopamine receptors, and in palliative care it pulls double duty: it manages nausea and vomiting (which become common as the body shuts down) and helps control delirium, a confused and sometimes agitated state that affects many people near death.
In a hospice study of 119 patients, the average dose was about 2 mg per 24 hours. Roughly a third of patients reported benefit within 48 hours, while harm (mainly drowsiness and urinary retention) was seen in about 12% over ten days.9PubMed Central. Pharmacovigilance in Hospice/Palliative Care: Net Effect of Haloperidol for Delirium That benefit-to-harm ratio reflects the reality of end-of-life medicine: you are not curing anything but trying to make the remaining time as comfortable as possible, and a medication that helps a third of patients while causing notable harm in a much smaller fraction is often worth trying.
An alternative to haloperidol is levomepromazine, which has broader sedative and antiemetic properties. Some palliative care teams use it as a second-line option when haloperidol alone is not controlling symptoms. The choice between them depends on the clinical picture: haloperidol is preferred for nausea and mild-to-moderate delirium, while levomepromazine may be brought in when more sedation is needed or when symptoms are refractory.
How These Medications Are Given
By the time someone needs these four drugs, swallowing tablets is usually no longer possible. The most common route is subcutaneous injection, where the medication is delivered just under the skin using a small needle. This is straightforward enough that community nurses and even trained family caregivers can do it at home.
In the UK, continuous subcutaneous infusion via a syringe driver has been a standard method since the early 1980s.10PubMed. The syringe driver and the subcutaneous route in palliative care: the inventor, the history and the implications The device slowly pushes a pre-loaded syringe of medication over 24 hours, providing steady symptom control without repeated injections. A multicentre survey of UK palliative care services confirmed that syringe drivers are used routinely.11PubMed. Drugs given by a syringe driver: a prospective multicentre survey of palliative care services in the UK Several of the four drugs can often be mixed in a single syringe driver, though compatibility needs to be checked.
Other routes exist as well. Midazolam can be given intranasally, as the clinical trial mentioned earlier demonstrated, and some anticholinergics like atropine are available as sublingual drops placed under the tongue. The key principle is flexibility: whatever route gets the drug into the body effectively when someone can no longer swallow.
Anticipatory Prescribing and “Just-in-Case” Kits
One of the most practical aspects of the four end-of-life drugs is that they are often prescribed before they are needed. In the UK, this is known as anticipatory or “just-in-case” prescribing. A doctor writes prescriptions for all four medications, and a kit is placed in the patient’s home along with clear instructions. This means that when a symptom flares at 2 a.m., a visiting nurse can administer medication immediately rather than waiting for a new prescription.1PubMed Central. Anticipatory prescribing in community end-of-life care: systematic review and narrative synthesis of the evidence since 2017
Nurses working in community settings have described how having these kits available helps them respond quickly and avoid unnecessary hospital admissions or urgent medical callouts.12PubMed Central. Administering anticipatory medications in end-of-life care: a qualitative study of nursing practice in the community and in nursing homes For the patient and family, staying at home and avoiding a disruptive ambulance ride is often a major priority.
However, the presence of injectable medications in the home raises its own challenges. Caregivers report varying levels of confidence when it comes to administering the drugs.13PubMed. Supporting Family Caregivers With Palliative Symptom Management: A Qualitative Analysis of the Provision of an Emergency Medication Kit in the Home Setting Some family members feel empowered; others are anxious about doing it wrong, giving too much, or making things worse. Good communication from the care team, including clear labeling, written instructions, and a phone number to call for guidance, makes a significant difference in how well the kit is used.
When Kidney Function Is Failing
As someone approaches death, their kidneys often stop working well, or they may have had chronic kidney disease for years. This matters because certain opioids depend on the kidneys to clear their breakdown products from the body. When those products accumulate, they can cause confusion, excessive sedation, or even seizures.
Morphine is one of the opioids most affected by kidney failure. Its metabolites build up and can become toxic, which is why clinical guidelines recommend avoiding morphine and codeine in patients with significant renal impairment.14PubMed. Opioids in renal failure and dialysis patients Fentanyl and methadone are considered safer alternatives because they are broken down by the liver into inactive products. Transdermal fentanyl and buprenorphine, both liver-metabolized, do not need dose adjustment for kidney problems and are recommended options in older adults with chronic kidney disease.15PubMed Central. Opioid Management in Older Adults with Chronic Kidney Disease: A Review
This is a practical point that families should be aware of. If a loved one has known kidney problems, the opioid component of the end-of-life kit may be fentanyl or hydromorphone rather than morphine. The goal is the same, but the specific drug is chosen to avoid compounding problems in a body that is already shutting down.
Does Using These Drugs Hasten Death?
This is one of the most common fears among families, and it deserves a direct answer. A review in The Lancet Oncology examined the evidence on opioid and sedative use in palliative care and concluded that while patients tend to receive higher doses of both as they get closer to death, there is no evidence that starting these medications or increasing their doses actually shortens life.16The Lancet Oncology. Patterns of use of opioids and sedatives at the end of life In other words, the drugs follow the dying process rather than driving it. People need more medication as their symptoms intensify, and the timing of death appears to be determined by the illness, not the treatment.
This finding is important because it challenges the so-called “double effect” worry, the idea that giving enough morphine to control pain might unintentionally hasten someone’s death. The Lancet Oncology review argued that the doctrine of double effect may not even be needed to justify opioid use in this context, since the feared shortening of life does not appear to happen. The review went further, suggesting that the persistent belief in this myth may actually act as a deterrent to good symptom control, with clinicians or families under-dosing out of misplaced fear.
Palliative Sedation When Standard Drugs Are Not Enough
Sometimes the standard four medications, even at escalated doses, do not adequately control symptoms. A small number of patients develop what clinicians call refractory suffering: pain, agitation, or breathlessness that resists every conventional treatment. In these cases, palliative sedation may be considered, where medication is used to reduce a person’s consciousness enough to relieve their distress.
The revised European Association for Palliative Care framework emphasizes a stepwise approach to palliative sedation, guided by the principle of proportionality: using only as much sedation as needed to make the suffering tolerable.17PubMed Central. Revised European Association for Palliative Care (EAPC) recommended framework on palliative sedation: An international Delphi study The framework stresses identifying and treating reversible causes of agitation first and places strong emphasis on patient autonomy. It deliberately avoids specifying a fixed remaining life expectancy as a prerequisite, recognizing that predicting time of death is imprecise.
Midazolam is typically the first drug used for palliative sedation. When it fails to achieve adequate sedation, propofol, an anesthetic agent more commonly associated with operating rooms, has shown promise. A study of propofol-based palliative sedation using low, incremental doses found excellent results in achieving adequate sedation without causing respiratory depression.18PubMed. Successful Use of Propofol After Failed Palliative Sedation in Patients With Refractory Symptoms Propofol requires more specialized monitoring and is not typically part of a home-based kit, but its availability gives palliative care teams a backup option for the most difficult cases.
Practical and ethical considerations surrounding palliative sedation remain important. Specialist advice is often recommended before initiating it, and the decision should involve the patient (if still able to participate), family, and the clinical team.19PubMed Central. Palliative sedation at the end of life: Practical and ethical considerations The line between adequate symptom relief and continuous deep sedation is one that clinicians navigate carefully, and transparency with families about the intent and expected outcomes helps maintain trust.
Children at the End of Life
The same four symptom categories, pain, breathlessness, agitation, nausea, arise in children who are dying, but the pharmacological approach has its own challenges. Children span a wide range of body sizes and developmental stages, and the opioid doses required can vary enormously. Published literature and clinical experience show an impressive range of opioid dosages needed in pediatric end-of-life care, reflecting how differently individual children metabolize and respond to these drugs.20PubMed Central. Ensuring pain relief for children at the end of life
When opioids alone cannot control pain, particularly neuropathic pain (the burning, shooting type caused by nerve damage), ketamine has emerged as a useful add-on. A case series of 14 children with opioid-resistant neuropathic pain found that all reported pain relief with ketamine, and nearly 80% experienced no side effects. In most cases, the addition of ketamine also allowed the opioid dose to be reduced.21PubMed Central. Refractory symptoms in paediatric palliative care: can ketamine help? Ketamine is not part of the standard four-drug kit, but it is an important tool in the pediatric palliative medicine cabinet, especially when conventional approaches have been exhausted.
Access Gaps Around the World
The four end-of-life drugs are inexpensive and well-established, yet huge portions of the world’s population cannot access them. The barriers are not scientific but bureaucratic and structural. Complex import regulations, limited local manufacturing, and restricted supply chains mean that opioids in particular are often inconsistently available in low- and middle-income countries.22PubMed Central. Confronting global inequities in palliative care Fears about misuse and addiction, while valid in some contexts, have driven policies in many countries that effectively lock patients out of pain relief during dying.
The result is a stark global divide. A person dying of cancer in the UK may have a just-in-case kit of four drugs waiting in their bedroom, while a person dying of the same cancer in parts of sub-Saharan Africa or South Asia may have access to none of them. Organizations advocating for palliative care equity have pointed out that access to pain relief at the end of life is not a luxury but a basic health right, and that overly restrictive opioid regulations do more harm than good when they leave dying people in untreated pain.